Maio, Michele <br/><br/>
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.  [electronic resource] 

 -  The Lancet. Oncology  09 2017 
 - 1261-1273 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(17)30446-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--therapeutic use<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mesothelioma--drug therapy<br/>Mesothelioma, Malignant<br/>Middle Aged<br/>Response Evaluation Criteria in Solid Tumors<br/>Survival Rate<br/>Treatment Outcome